Literature DB >> 33634806

Polysaccharides from fermented Momordica charantia L. with Lactobacillus plantarum NCU116 ameliorate metabolic disorders and gut microbiota change in obese rats.

Jia-Jia Wen1, Ming-Zhi Li, He Gao, Jie-Lun Hu, Qi-Xing Nie, Hai-Hong Chen, Yan-Li Zhang, Ming-Yong Xie, Shao-Ping Nie.   

Abstract

Obesity is a chronic disease characterized by overweight resulting from fat accumulation, along with disturbance of metabolism and gut microbiota. Fermentation, as a green processing method, is beneficial for improving the nutrition capacity of food components. Polysaccharides are considered as one of the important components in food and are also potential supplements for anti-obesity treatment. This study aimed to investigate the anti-obesity effects of polysaccharides from fermented and non-fermented Momordica charantia L. with Lactobacillus plantarum NCU116 (FP and NFP) on obese rats by serum metabolomics and gut microbiota analysis. Metabolomics results revealed that abnormal lipid metabolism was formed due to obesity. The supplement of FP and NFP improved the glycerophospholipids, glycosphingolipids, and amino acid metabolism of the obese rats, which alleviated the hypercholesterolemia and overweight in rats. Furthermore, the disorder of gut microbiota was ameliorated by FP and NFP. FP promoted the growth of beneficial bacteria, such as phylum Firmicutes, Actinobacteria, and genera Anaerostipes, Coprococcus, Lactobacillus, and Bifidobacterium. FP also reduced several harmful bacteria belonging to the phylum Proteobacteria and genera Helicobacter. The positive correlation of the weight loss and lowering of serum lipids with the increased beneficial bacteria further elucidated that the anti-obesity effect of FP in obese rats is associated with the regulation of gut microbiota and serum metabolites. The results of this study could provide information for developing probiotic products in the future that may have beneficial effects on the prevention or treatment of obesity.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33634806     DOI: 10.1039/d0fo02600j

Source DB:  PubMed          Journal:  Food Funct        ISSN: 2042-6496            Impact factor:   5.396


  7 in total

Review 1.  Targeting Gut Microbiota With Natural Polysaccharides: Effective Interventions Against High-Fat Diet-Induced Metabolic Diseases.

Authors:  Chao-Yue Sun; Zuo-Liang Zheng; Cun-Wu Chen; Bao-Wei Lu; Dong Liu
Journal:  Front Microbiol       Date:  2022-03-15       Impact factor: 5.640

2.  Extraction, isolation, structural characterization, and antioxidant activity of polysaccharides from elderberry fruit.

Authors:  Xinxin Wei; Junxiu Yao; Fangzhou Wang; Dejun Wu; Rentang Zhang
Journal:  Front Nutr       Date:  2022-07-19

3.  Kidney Bean Fermented Broth Alleviates Hyperlipidemic by Regulating Serum Metabolites and Gut Microbiota Composition.

Authors:  Weiqiao Pang; Di Wang; Zhaohang Zuo; Ying Wang; Wei Sun; Naidan Zhang; Dongjie Zhang
Journal:  Nutrients       Date:  2022-08-05       Impact factor: 6.706

4.  Variation in characterization and probiotic activities of polysaccharides from litchi pulp fermented for different times.

Authors:  Chunmei He; Ruifen Zhang; Xuchao Jia; Lihong Dong; Qin Ma; Dong Zhao; Zhida Sun; Mingwei Zhang; Fei Huang
Journal:  Front Nutr       Date:  2022-08-24

5.  Portulaca oleracea polysaccharides reduce serum lipid levels in aging rats by modulating intestinal microbiota and metabolites.

Authors:  Qiang Fu; Hui Huang; Aiwen Ding; Ziqi Yu; Yuping Huang; Guiping Fu; Yushan Huang; Xiaoliu Huang
Journal:  Front Nutr       Date:  2022-08-02

6.  Huangshan Maofeng Green Tea Extracts Prevent Obesity-Associated Metabolic Disorders by Maintaining Homeostasis of Gut Microbiota and Hepatic Lipid Classes in Leptin Receptor Knockout Rats.

Authors:  Guohuo Wu; Wei Gu; Huijun Cheng; Huimin Guo; Daxiang Li; Zhongwen Xie
Journal:  Foods       Date:  2022-09-20

Review 7.  Phenolic Bioactives From Plant-Based Foods for Glycemic Control.

Authors:  Dipayan Sarkar; Ashish Christopher; Kalidas Shetty
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-18       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.